


Key to new lupus treatment could depend on protein in the blood

December 14 2022



Serum CXCL5 levels are lower in Asian SLE patients and Fas^{lpr} mice, compared to healthy individuals and ICR mice controls, and negatively correlated with disease activity. (A) Serum CXCL5 levels in healthy individuals and Asian active SLE patients. (B) Correlation of serum CXCL5 and SLE disease activity index

(SLEDAI) scores in Asian SLE patients. (C) Human receptor CXCR1/2 expression in the blood neutrophils. (D) Plasma levels of CXCL5 in healthy immunocompetent ICR mice and Fas^{lpr} mice with increasing age. (E) Anti-dsDNA antibody levels with increasing age of Fas^{lpr} mice. Six to 8 Fas^{lpr} mice per time point. (F) Urinary albumin-creatinine ratio (ACR) with increasing age of Fas^{lpr} mice. Six to 8 Fas^{lpr} mice per time point for the first 4 time points; three mice per time point for the last 2 time points. In total, 16 healthy and 20 SLE patient blood samples, 15 ICR and 57 Fas^{lpr} mice were used for this experiment. The results are expressed as the mean \pm SD. Statistical significance was defined as * p

Citation: Key to new lupus treatment could depend on protein in the blood (2022, December 14) retrieved 19 December 2022 from <https://medicalxpress.com/news/2022-12-key-lupus-treatment-protein-blood.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.